India’s regulatory environment surrounding pharmaceuticals and medical devices needs to evolve in order to unlock the industries’ true potential, says Kirit Javali of Jafa & Javali.
A new EU regulation on implantable medical devices takes steps to acknowledge that patient outcomes and safety are primary goals, but the transition to the new system might not be easy for industry stakeholders, says Jo Emmett of Premier Research.
As securing patent eligibility for ‘healthcare IT’ applications seems to be becoming easier, companies looking to monetise IP in this area can breathe a sigh of relief. Stacy Taylor of DLA Piper explains more.
IP law has yet to catch up with the technological capabilities of 3D printing, but by taking pre-emptive action, companies can maximise their IP protection under the current legal framework. Arlene Chow and Nitya Anand of Hogan Lovells report.
On December 7, LSIPR will be hosting the Life Sciences Patents Network Europe 2016 at the Bloomsbury Hotel in London. Here we preview the main talking points.
A decision by Germany’s Federal Court of Justice has developed the concept of the ‘doctrine of equivalents’, possibly benefiting pharma patent owners, say Bernd Allekotte and Markus Grammel of Grünecker.
Ahead of the Life Sciences IP Summit 2016 from October 20 to 21 at the Hilton London Paddington Hotel, Sarah Porch of C5 previews the main talking points, including Brexit and the UPC.
The pharmaceutical industry needs to adjust its expectations of the scope of IP protection available in the digital age, say Stephen Bennett, Elisabethann Wright and Mark Marfe of Hogan Lovells, and James Cross of RGC Jenkins.
Brexit will have significant consequences for the UK regarding SPCs and the unitary patent system, while the UPC’s proposed start date of early 2017 looks highly unlikely, say Christopher Stothers and Paul Abbott of Arnold & Porter.
The US Supreme Court’s Mayo and Myriad decisions have brought challenges to subject matter eligibility to the forefront in the biomedical industry, but they do not signal the end of biomedical patents. Pat Carson and Mira Atanassova Mulvaney of Kirkland & Ellis report.